Allogene stock sails after CAR T clears residual lymphoma in early data cut
BioSpace
Pivotal findings for the off-the-shelf cell therapy surpassed William Blair's expectations and sent Allogene Therapeutics' stock up more than 50% in pre-market trading Monday morning.
pharminent
April 13, 2026 (Last updated: April 13, 2026)
BioSpace
Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.